Crolibulin

Crolibulin (EPC2407) is a tubulin polymerization inhibitor, with potent apoptosis induction and cell growth inhibition. Crolibulin has anti-tumor activity. Crolibulin also has cardiovascular toxicity and neurotoxicity[1][2][3].

Product Specifications

CAS Number

[1000852-17-4]

Product Name Alternative

EPC2407

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Apoptosis; Microtubule/Tubulin

Type

Reference compound

Related Pathways

Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton

Applications

Cancer-programmed cell death

Field of Research

Cancer; Cardiovascular Disease

Assay Protocol

https://www.medchemexpress.com/Crolibulin.html

Concentration

10mM

Purity

98.96

Solubility

DMSO : 125 mg/mL (ultrasonic; warming)

Smiles

N#CC1=C(N)OC2=C(N)C(N)=CC=C2[C@H]1C3=CC(OC)=C(OC)C(Br)=C3

Molecular Formula

C18H17BrN4O3

Molecular Weight

417.26

Precautions

H302, H315, H319

References & Citations

[1]Kalmuk J, et al. Multimodal imaging guided preclinical trials of vascular targeting in prostate cancer. Oncotarget. 2015 Sep 15;6 (27) :24376-92.|[2]Zhai X, et al. Discovery and Optimization of Novel 5-Indolyl-7-arylimidazo[1,2-a]pyridine-8-carbonitrile Derivatives as Potent Antitubulin Agents Targeting Colchicine-binding Site. Sci Rep. 2017 Feb 27;7:43398.|[3]S. P. Anthony, et al. EPC2407, a new beta-tubulin vascular disrupting agent with potent apoptosis and cell growth inhibition. Journal of Clinical Oncology 25, no. 18_suppl (June 20, 2007) 14043-14043.